CSRT.L Regulatory News (CSRT)

Consort Medical plc

25 November 2016

CFO Appointment

Consort Medical plc ("Consort Medical", "Consort" or the "Group") (LSE: CSRT), announces that Paul Hayes, Group Finance Director of The Vitec Group plc, is to succeed Richard Cotton as Consort Medical's Group Chief Financial Officer ("CFO"). He will join the Company as CFO and an Executive Director on the Board on 1 May 2017.

As previously announced, Richard will leave Consort after the half year results in December 2016. In the intervening period, Consort also announces the appointment of David Tilston as interim CFO to help effect a smooth transition with Paul when he joins on 1 May 2017.

Paul is an experienced finance director in multi-national high technology manufacturing, consumer goods and retail businesses. Paul has gained considerable experience during his five year tenure at The Vitec Group plc where he has built on his strong track record in operational management, delivering profitable growth and leading commercial, well-controlled finance functions.

Previously, Paul was Group Financial Controller at Signet Jewellers Limited (formerly Signet Group plc) between 2007 and 2011. Prior to that, he held a senior director role at RHM plc from 2004 to 2007, assisting with its flotation in 2005 and subsequent sale to Premier Foods plc. Paul was with Smiths Group plc for over ten years from 1993, including a number of divisional and operating company finance director roles. Paul is a Chartered Accountant having qualified with Ernst and Young and has a first class Masters degree in Mechanical Engineering, Manufacture & Management.

David joins the Company having previously held a number of senior executive finance director roles, including Innovia Group, Mouchel Group plc, Findel plc, SABMiller plc and SThree plc.

Dr Peter Fellner, Chairman of Consort Medical, commented:

"We look forward to welcoming Paul to Consort Medical. His strong track record in driving sustainable profitable growth in high technology manufacturing businesses will be a great asset to the Company as we continue to reinforce our position as a leading provider of drug delivery solutions."

Paul Hayes added:

"I am delighted to be joining Consort Medical and help build on its leading position as a global contract development and manufacturing organisation. I look forward to working with the Executive team and the Board as the Company continues to deliver strong organic growth from its robust and innovative product and pipeline portfolios."

There is no further information required to be disclosed pursuant to paragraph 9.6.13R of the Listing Rules in respect of Mr Hayes.

- ENDS -

Enquiries:

About Consort Medical

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

Our businesses

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectable products and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.